Molecules (Jul 2020)

Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1

  • Irina V. Il’ina,
  • Nadezhda S. Dyrkheeva,
  • Alexandra L. Zakharenko,
  • Alexander Yu. Sidorenko,
  • Nikolay S. Li-Zhulanov,
  • Dina V. Korchagina,
  • Raina Chand,
  • Daniel M. Ayine-Tora,
  • Arina A. Chepanova,
  • Olga D. Zakharova,
  • Ekaterina S. Ilina,
  • Jóhannes Reynisson,
  • Anastasia A. Malakhova,
  • Sergey P. Medvedev,
  • Suren M. Zakian,
  • Konstantin P. Volcho,
  • Nariman F. Salakhutdinov,
  • Olga I. Lavrik

DOI
https://doi.org/10.3390/molecules25153496
Journal volume & issue
Vol. 25, no. 15
p. 3496

Abstract

Read online

Two novel structural types of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors with hexahydroisobenzofuran 11 and 3-oxabicyclo [3.3.1]nonane 12 scaffolds were discovered. These monoterpene-derived compounds were synthesized through preliminary isomerization of (+)-3-carene to (+)-2-carene followed by reaction with heteroaromatic aldehydes. All the compounds inhibit the TDP1 enzyme at micro- and submicromolar levels, with the most potent compound having an IC50 value of 0.65 μM. TDP1 is an important DNA repair enzyme and a promising target for the development of new chemosensitizing agents. A panel of isogenic clones of the HEK293FT cell line knockout for the TDP1 gene was created using the CRISPR-Cas9 system. Cytotoxic effects of topotecan (Tpc) and non-cytotoxic compounds of the new structures were investigated separately and jointly in the TDP1 gene knockout cells. For two TDP1 inhibitors, 11h and 12k, a synergistic effect was observed with Tpc in the HEK293FT cells but was not found in TDP1 −/− cells. Thus, it is likely that the synergistic effect is caused by inhibition of TDP1. Synergy was also found for 11h in other cancer cell lines. Thus, sensitizing cancer cells using a non-cytotoxic drug can enhance the efficacy of currently used pharmaceuticals and, concomitantly, reduce toxic side effects.

Keywords